GM-CSF-neutralizing scFv
Showing 1 - 25 of 2,214
COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)
Recruiting
- COVID-19
- NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
-
Chongqing, ChinaChongqing Public Health Medical Center
Nov 16, 2020
Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)
Recruiting
- Neuroblastoma
- GM-CSF + Naxitamab
-
Gainesville, Florida
- +22 more
Aug 29, 2022
HIV Trial in United States (APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim)
Completed
- HIV Infections
- APL 400-047
- +2 more
-
Birmingham, Alabama
- +3 more
Oct 28, 2021
Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)
Active, not recruiting
- Neuroblastoma
- Hu3F8
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 1, 2022
Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)
Not yet recruiting
- Carcinoma
- Solid Tumor
- ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 26, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Thymalfasin
- +3 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRĪ± peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Multiple Myeloma Trial in United States (procedure, drug, biological)
Completed
- Multiple Myeloma
- Tumor Cell Collection
- +6 more
-
San Francisco, California
- +14 more
Jul 11, 2022
Transplant-Related Hematologic Malignancy Trial in Atlanta (Sargramostim, Control Arm)
Recruiting
- Transplant-Related Hematologic Malignancy
- Sargramostim
- Control Arm
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))
Active, not recruiting
- Renal Cancer
- Dendritic Cell Tumor Fusion Vaccine
- Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 2, 2023
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 Trial in United States (drug, other,
Active, not recruiting
- Bilateral Breast Carcinoma
- +11 more
- Cyclophosphamide
- +4 more
-
Scottsdale, Arizona
- +11 more
Jan 12, 2023
Objective Response Rate Trial in Wuhan (GM-CSF)
Recruiting
- Objective Response Rate
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University
Feb 25, 2023
Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)
Recruiting
- Recurrent Osteosarcoma
- humanized anti-GD2 antibody
- GM-CSF
-
Los Angeles, California
- +2 more
Dec 22, 2022
Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)
Recruiting
- Neuroblastoma Recurrent
- Natural killer cell
- +4 more
-
Hong Kong, Hong KongHong Kong Children's Hospital
Feb 22, 2023
Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)
Terminated
- Hepatitis B, Chronic
- Granulocyte Macrophage-colony Stimulating Factor
- Entecavir
-
Beijing, Beijing, China302 Military Hospital
Mar 9, 2022
Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)
Recruiting
- Advanced Refractory Solid Tumors
- Hypofractionated radiotherapy
- +3 more
-
Beijing, China
- +15 more
Aug 8, 2022
NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Vinorelbine
- +4 more
-
Suzhou, ChinaSecond Affiliated Hospital of Soochow University
Oct 29, 2022
Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)
Active, not recruiting
- Ependymoma, Recurrent Childhood
- Ependymoma
- Granulocyte Macrophage Colony Stimulation Factor
-
Denver, Colorado
- +1 more
Feb 8, 2022
Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)
Recruiting
- Colorectal Neoplasms
- hypofractionation Radiotherapy
- +3 more
-
Xiamen, Fujian, ChinaThe First Affiliated Hospital of Xiamen University
Mar 28, 2022
Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)
Active, not recruiting
- Neuroblastoma
- Hu3F8 With GM-CSF
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 2, 2022
Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab
Recruiting
- Unresectable Melanoma
- +3 more
- Sargramostim (GM-CSF)
- Pembrolizumab (anti-PD-1)
-
Boston, Massachusetts
- +1 more
Jul 6, 2022
Down Syndrome Trial in Aurora (Sargramostim for Injection, Saline Placebo)
Not yet recruiting
- Down Syndrome
- Sargramostim for Injection
- Saline Placebo
-
Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
Jul 28, 2022
Neuroblastoma, Pediatric Solid Tumor Trial in Boston (procedure, biological, drug)
Recruiting
- Neuroblastoma
- Pediatric Solid Tumor
- Tissue collection
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 17, 2022